NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

ROSE for Improved Molecular Marker Testing Via EBUS

Enrolling By InvitationNA

Sponsor: Johns Hopkins University

Conditions: Non-small Cell Lung Cancer (NSCLC)

Interventions: ROSE (presence of cytotech) & liquid prep, NO-ROSE (absence of cytotech) & liquid prep, ROSE (presence of cytotech) & tissue clot sample, NO-ROSE (absence of cytotech) & tissue clot sample

Countries: United States

This research study is being done to compare two ways to conduct bronchoscopic biopsy of lymph nodes and other structures in the chest (i.e. the presence or absence of an on-site cytotechnologist performing a limited microscopic evaluation to provide non-binding feedback on specimen adequacy in real time during the procedure).

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Inpatients or outpatients \>18 years old
* Capable of informed consent
* Known or suspected non-small cell lung cancer (NSCLC)
* Referred to the interventional pulmonary team at Johns Hopkins Hospital (JHH), Johns Hopkins Bayview Medical Center (JHBMC), or other participating sites for tissue sampling of a hilar/mediastinal lymph node or another lesion accessible by convex-probe (CP) EBUS

Exclusion Criteria:

* Refuse participation
* Standard contraindications to EBUS and bronchoscopy in general: bleeding disorders, antiplatelet or anticoagulant usage, high fraction of inspired oxygen (FiO2) requirement, and clinical instability
* Pregnant women
* Cytotechnologist not available at the time of screening, enrollment, or randomization

Locations (4)

Chicago, Illinois, United States
Baltimore, Maryland, United States
Baltimore, Maryland, United States
Charleston, South Carolina, United States